Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 1.0 %

EGRX stock opened at $6.07 on Monday. Eagle Pharmaceuticals has a 52 week low of $3.21 and a 52 week high of $23.52. The company has a market capitalization of $78.83 million, a price-to-earnings ratio of 5.14 and a beta of 0.51. The firm’s 50-day moving average is $4.38 and its two-hundred day moving average is $4.95.

Institutional Trading of Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC raised its position in shares of Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Eagle Pharmaceuticals by 623.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 5,896 shares in the last quarter. DGS Capital Management LLC bought a new stake in shares of Eagle Pharmaceuticals in the 4th quarter worth approximately $60,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Eagle Pharmaceuticals in the 1st quarter worth approximately $83,000. Finally, Aristides Capital LLC bought a new stake in shares of Eagle Pharmaceuticals in the 4th quarter worth approximately $86,000. 85.36% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.